After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Novavax, Inc. is $628.40M. A total of 18.36 million shares were traded on the day, compared to an average of 8.20M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NVAX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 21 BUYs and 11 SELLs from insiders. Insiders purchased 72,911 shares during that period but sold 20,087.
In the most recent transaction, Glenn Gregory M bought 1,000 shares of NVAX for 6.50 per share on Mar 10. After the transaction, the President, R&D now owns 14,473 company shares. In a previous transaction on Mar 07, Glenn Gregory M bought 2,000 shares at 7.04 per share. NVAX shares that President, R&D owns now total 13,473.
Among the insiders who bought shares, Glenn Gregory M acquired of 3,000 shares on Mar 06 at a per-share price of $7.48. This resulted in the President, R&D holding 11,473 shares of NVAX after the transaction.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NVAX in the last 3 months, the mean price target is $19.20 with high estimates of $38.00 and low estimates of $4.00. In terms of 52-week highs and lows, NVAX has a high of $11.36 and a low of $3.53.
As of this writing, NVAX has an earnings estimate of -$0.45 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $0.08 per share and a lower estimate of -$1.29. The company reported an EPS of $0.58 in the last quarter, which was 141.70% higher than expectations of -$1.39.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NVAX’s latest balance sheet shows that the firm has $1.52B in Cash & Short Term Investments as of fiscal 2021. There were $453.99M in debt and $2.39B in liabilities at the time. Its Book Value Per Share was -$5.71, while its Total Shareholder’s Equity was -$351.67M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NVAX is Buy with a score of 3.50.
